Hemostemix Inc.
HMTXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $385 | $623 | $180 |
| G&A Expenses | $1,459 | $1,328 | $3,433 | $5,982 |
| SG&A Expenses | $1,976 | $1,948 | $3,892 | $6,475 |
| Sales & Mktg Exp. | $516 | $620 | $459 | $493 |
| Other Operating Expenses | $0 | $0 | -$1,241 | $1 |
| Operating Expenses | $1,979 | $2,333 | $3,273 | $6,656 |
| Operating Income | -$1,979 | -$2,333 | -$3,273 | -$6,666 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$638 | -$169 | -$1,475 | $125 |
| Pre-Tax Income | -$2,616 | -$2,502 | -$4,749 | -$6,542 |
| Tax Expense | $0 | $0 | $487 | -$256 |
| Net Income | -$2,616 | -$2,502 | -$5,235 | -$6,286 |
| % Margin | – | – | – | – |
| EPS | -0.028 | -0.03 | -0.075 | -0.11 |
| % Growth | 9.2% | 59.5% | 32% | – |
| EPS Diluted | -0.028 | -0.03 | -0.075 | -0.11 |
| Weighted Avg Shares Out | 93,442 | 82,501 | 69,981 | 57,450 |
| Weighted Avg Shares Out Dil | 95,059 | 82,499 | 69,981 | 57,450 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $73 |
| Interest Expense | $625 | $0 | $350 | $10 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$1,979 | -$2,333 | -$3,273 | -$2,768 |
| % Margin | – | – | – | – |